Town & Country Bank & Trust CO dba First Bankers Trust CO Sells 5,515 Shares of Danaher Corporation $DHR

Town & Country Bank & Trust CO dba First Bankers Trust CO lowered its stake in Danaher Corporation (NYSE:DHR) by 82.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,199 shares of the conglomerate’s stock after selling 5,515 shares during the quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Danaher were worth $238,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sivia Capital Partners LLC raised its holdings in shares of Danaher by 6.3% in the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock valued at $397,000 after purchasing an additional 119 shares during the last quarter. Capital Investment Advisors LLC increased its stake in Danaher by 1.2% in the 2nd quarter. Capital Investment Advisors LLC now owns 7,352 shares of the conglomerate’s stock valued at $1,452,000 after buying an additional 85 shares during the last quarter. PFG Investments LLC increased its stake in Danaher by 4.6% in the 2nd quarter. PFG Investments LLC now owns 5,233 shares of the conglomerate’s stock valued at $1,034,000 after buying an additional 228 shares during the last quarter. Childress Capital Advisors LLC lifted its position in Danaher by 10.6% during the 2nd quarter. Childress Capital Advisors LLC now owns 1,797 shares of the conglomerate’s stock worth $355,000 after buying an additional 172 shares in the last quarter. Finally, Community Financial Services Group LLC boosted its stake in shares of Danaher by 5.2% during the 2nd quarter. Community Financial Services Group LLC now owns 19,371 shares of the conglomerate’s stock worth $3,827,000 after buying an additional 960 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Stock Down 2.2%

Shares of DHR opened at $219.62 on Friday. The company has a current ratio of 1.87, a quick ratio of 1.10 and a debt-to-equity ratio of 0.35. Danaher Corporation has a 12 month low of $171.00 and a 12 month high of $242.80. The firm’s 50 day moving average is $230.77 and its 200-day moving average is $213.81. The stock has a market capitalization of $155.13 billion, a PE ratio of 43.58, a P/E/G ratio of 3.42 and a beta of 0.89.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Wednesday, January 28th. The conglomerate reported $2.23 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.09. The firm had revenue of $6.84 billion for the quarter, compared to analyst estimates of $6.79 billion. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The company’s revenue was up 4.6% on a year-over-year basis. During the same quarter last year, the company earned $2.14 EPS. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. Equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Friday, December 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio is currently 26.39%.

Insiders Place Their Bets

In related news, Director Teri List sold 3,298 shares of Danaher stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director directly owned 20,762 shares of the company’s stock, valued at $4,702,593. This trade represents a 13.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Brian W. Ellis sold 21,776 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,248 shares of company stock worth $6,609,663 over the last ninety days. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Barclays upped their target price on Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Evercore ISI reiterated an “outperform” rating and set a $254.00 price objective on shares of Danaher in a research note on Wednesday. Redburn Partners set a $220.00 price target on shares of Danaher in a research report on Wednesday, October 8th. KeyCorp reissued an “overweight” rating on shares of Danaher in a research report on Thursday. Finally, Morgan Stanley started coverage on shares of Danaher in a report on Monday, December 1st. They issued an “overweight” rating and a $270.00 target price on the stock. Twenty investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $252.55.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher beat Q4 consensus — reported $2.23 EPS vs. ~$2.14 expected and revenue $6.84B topping estimates, showing growth across Life Sciences, Diagnostics and Bioprocessing. PR Newswire: Q4 Results
• Positive Sentiment: Analyst support: JPMorgan raised its price target to $275 and kept an Overweight rating, highlighting upside vs. current levels and supporting longer‑term conviction. Benzinga: JPMorgan PT Raise
• Neutral Sentiment: FY‑2026 EPS guidance of $8.35–$8.50 was issued and sits essentially inline with the Street (~$8.42), so the outlook is credible but not a positive catalyst above expectations. Reuters: 2026 Forecast
• Neutral Sentiment: Management highlighted strong free cash flow and balance‑sheet strength, which supports buybacks/dividends and long‑term investment in bioprocessing but is not a near‑term growth surprise. TipRanks: Cash Strength
• Negative Sentiment: Market reaction: shares fell after the print as investors parsed the in‑line guidance and cautious commentary on end‑market recovery, leading to short‑term selling despite the beat. Seeking Alpha: Stock Drops
• Negative Sentiment: Commentary emphasized a gradual (not rapid) recovery in pharma spending and continued weakness in some academic research markets — investors looking for a stronger acceleration may have reduced exposure. Benzinga: Gradual Improvement

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.